Ovid Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Ovid Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2016 to Q3 2024.
  • Ovid Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$14M, a 24.5% decline year-over-year.
  • Ovid Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$32.5M, a 33% increase year-over-year.
  • Ovid Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$52.3M, a 3.38% increase from 2022.
  • Ovid Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$54.2M, a 144% decline from 2021.
  • Ovid Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $123M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$32.5M -$14M -$2.75M -24.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$29.7M $8.52M +$20.9M Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-12
Q1 2024 -$50.7M -$11.7M +$1.66M +12.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-12
Q4 2023 -$52.3M -$15.3M -$3.82M -33.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-08
Q3 2023 -$48.5M -$11.3M +$715K +5.97% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$49.2M -$12.4M +$2.18M +14.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-12
Q1 2023 -$51.4M -$13.4M +$2.75M +17.1% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-12
Q4 2022 -$54.2M -$11.5M +$14.5M +55.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-08
Q3 2022 -$68.7M -$12M -$584K -5.13% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$68.1M -$14.6M +$1.2M +7.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-03
Q1 2022 -$69.3M -$16.1M -$192M -109% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-03
Q4 2021 $123M -$26M -$3.97M -18% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-13
Q3 2021 $127M -$11.4M +$5.04M +30.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $122M -$15.8M +$6.76M +30% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-08
Q1 2021 $115M $176M +$196M Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-08
Q4 2020 -$81M -$22M -$5.06M -29.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-15
Q3 2020 -$76M -$16.4M +$210K +1.26% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$76.2M -$22.6M -$9.49M -72.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-10
Q1 2020 -$66.7M -$20M -$6.23M -45.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-10
Q4 2019 -$60.5M -$17M -$4.07M -31.5% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-11
Q3 2019 -$56.4M -$16.6M -$3.67M -28.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-13
Q2 2019 -$52.7M -$13.1M -$122K -0.95% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-13
Q1 2019 -$52.6M -$13.8M -$617K -4.68% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-13
Q4 2018 -$52M -$12.9M -$1.94M -17.7% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-11
Q3 2018 -$50M -$13M -$3.6M -38.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-11
Q2 2018 -$46.4M -$12.9M -$2.69M -26.2% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-11
Q1 2018 -$43.7M -$13.2M +$21.1M +61.5% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-11
Q4 2017 -$64.8M -$11M -$3.4M -44.9% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-07
Q3 2017 -$61.4M -$9.36M -$3.57M -61.8% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-07
Q2 2017 -$57.8M -$10.2M -$4.86M -90.3% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-07
Q1 2017 -$53M -$34.2M -$30.6M -830% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-07
Q4 2016 -$22.4M -$7.56M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-29
Q3 2016 -$5.79M Jul 1, 2016 Sep 30, 2016 10-K 2018-03-29
Q2 2016 -$5.39M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-29
Q1 2016 -$3.68M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.